Kamada Signs $50 Million Contract for Texas Plasma Centers

The new contract changes one important part of the case for Kamada: demand for plasma from Houston and San Antonio no longer rests only on customer discussions. The company has signed a three-year supply agreement expected to generate approximately $50 million, with initial sales due in the fourth quarter of 2026. Dividing the contract value by three produces a simple annual average of about $16.7 million, close to the $16 million to $20 million combined annual revenue target previously assigned to the two centers at full capacity. That comparison gives the agreement real commercial weight, but it does not show that revenue will be evenly distributed or that the centers will quickly reach full utilization. Kamada disclosed no volume, price per liter, minimum purchase commitment, or margin. Expected fourth-quarter sales were also already included in 2026 guidance, so the agreement is not an automatic forecast increase. The current read is that customer-demand risk has fallen substantially, while margin and cash conversion remain the next proof points.

The Customer Gap Has Closed

At the beginning of the year, the company was still describing active discussions with potential customers and expected to start normal source plasma sales in the second half. It now has an agreement with a leading plasma-derived therapies company. Houston and San Antonio have gained an anchor customer and a multi-year sales path instead of relying solely on constructed capacity and regulatory approvals.

The disclosure does not close every question about contractual bindingness. Kamada says the agreement is expected to generate approximately $50 million, but it does not disclose minimum volumes, a delivery schedule, an obligation to pay for uncollected quantities, or termination provisions. The $50 million should therefore be treated as expected revenue under a signed agreement, not as a disclosed guaranteed cash commitment.

The counterparty also remains unnamed. A large customer reduces the risk that the new capacity will lack demand, but it creates reliance on one commercial relationship. That matters in a concentrated industry where a small number of large plasma-derived manufacturers source external plasma and normal source plasma prices can move with donor availability, collection capacity, and vertically integrated manufacturers' procurement decisions.

The Contract Envelope Matches Two Centers

The comparison with Kamada's earlier operating targets explains why this is more than another sales announcement.

The overlap between the $16.7 million simple average and the $16 million to $20 million combined center target is the contract's strongest signal. It suggests that one customer could represent a large part of the planned economics of Houston and San Antonio. However, the fourth-quarter start indicates that revenue may ramp gradually, and Kamada provided neither an annual allocation nor contracted liters. The agreement cannot be translated into utilization without the missing price, mix, and delivery schedule.

The sites also have a second role. Houston and San Antonio are designed to collect normal source plasma for external sales and specialty plasma for Kamada's own products. If the external customer uses a large share of capacity, investors will need to understand how management balances that demand against the goal of reducing third-party sourcing for its proprietary portfolio.

No 2026 Guidance Upgrade

Kamada explicitly said expected fourth-quarter sales were already included in its annual forecast. Current guidance remains $200 million to $205 million of revenue and $50 million to $53 million of adjusted EBITDA. Investors should not add a proportional share of the contract on top of those figures.

The 2026 contribution is also not one-third of the contract. Sales begin only in the fourth quarter, leaving most of the $50 million to be recognized after 2026. The company did not disclose whether volumes begin at a low level and rise or settle into a stable pace after launch.

That does not make the agreement irrelevant to guidance. In May, year-end plasma sales were still one of the assumptions supporting the forecast. The contract converts that assumption into an identified customer relationship and a stated sales window. It does not raise the forecast, but it reduces the risk that one embedded growth driver reaches year-end without a buyer.

Margin and Cash Are Now the Proof

In the first quarter, gross margin fell to 42% from 47% a year earlier because of sales mix. Operating cash flow was negative $0.3 million despite $4.1 million of net income, and a roughly $9.8 million increase in trade receivables was the largest operating cash use. Those figures were not caused by this contract, whose sales have not started. They show why additional revenue alone does not establish an attractive return from the centers.

Collection economics are determined after donor compensation, staffing, testing, logistics, and fixed site overhead. Kamada has previously warned that normal source plasma prices can fall below collection and overhead costs. The contract reduces uncertainty about the buyer, but the absent price and volume prevent a reliable gross-profit calculation.

There is also a disclosure limitation. Plasma collection and external plasma sales are included within the Proprietary Products segment alongside Kamada's major therapies. Without additional detail, the contract's contribution may be absorbed into the segment mix rather than appear as a separate profit line. Investors will therefore need to follow gross profit dollars, inventories, receivables, and operating cash flow, together with any disclosure of liters collected or center utilization.

The current conclusion is positive but bounded. Kamada has proven that a customer is willing to build a multi-year purchasing path at a value close to the two centers' combined full-capacity revenue target. It has not yet proven collection price, margin, or collection speed. The fourth quarter should deliver the first revenue evidence, followed by proof that sales add gross profit and cash without tying up an unusual amount in inventories and receivables.

The $50 million should not be read as immediate revenue or an addition to 2026 guidance. The agreement's value is that it moves the Texas centers from capacity seeking customers to capacity with a commercial path. If that path also appears in profit and cash, the Texas investment will progress from demand validation to return validation.